Valuation
- Market cap
- 36,896,000
- Revenue TTM
- $24,050,000
- Net income TTM
- $-360,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1.50%
- Debt to equity
- 0.02
Trading
- Volume
- 11,100
- Avg volume
- 111,550
- Day's range
- $19.95 – $20.65
- Shares out
- 1,790,000
- Stochastic %K
- 2%
- Beta
- 1.30
- Analysts
- Strong Buy
- Price target
- $40.00
Company profile
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clini...
Show more
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 203 787 7888
- Website
- https://www.precipiodx.com
- Address
- 4 Science Park, 3rd Floor, New Haven, United States
Latest news
No headlines yet.
